

Healthy Volunteers

A study to look at how safe different doses of a new study medicine (RO7303509) were for healthy people to take – and how this medicine was processed through the body

Trial Status
Completed

Trial Runs In
1 Country

Trial Identifier
GA42285

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A phase 1a, randomized, double#blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of RO7303509 in healthy volunteers

Trial Summary:

This clinical trial investigated a new medicine called, “RO7303509”, for the treatment of “systemic sclerosis”. This study was done to find out how safe it was for healthy people to get a single treatment of this study medicine. Different groups of people were given different doses of RO7303509. This was a phase 1a, randomized, double#blind, placebo-controlled, single ascending-dose study in healthy volunteers.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 1a Phase
--	--------------------------

GA42285
Trial Identifiers

Eligibility Criteria:

Gender
Both

Age
18 to 75 years

Healthy Volunteers
Yes

Healthy volunteers were enrolled at one study site in USA to evaluate the safety and tolerability of RO7303509, a treatment for systemic sclerosis. Forty-nine participants contributed to the final analyses of the safety data in this phase 1a, randomized, double#blind, placebo-controlled, single ascending-dose study. Results showed

ForPatients

by Roche

RO7303509 to be well tolerated; there were some low-grade common side effects, but no deaths, no serious side effects, or side effects leading to study discontinuations.